O-RAN-ALLIANCE
25.2.2020 10:02:10 CET | Business Wire | Press release
The O-RAN Alliance (O-RAN) and the Telecom Infra Project (TIP) have announced today a liaison agreement that ensures alignment in the shared focus area of developing interoperable open Radio Access Network (RAN) solutions.
The O-RAN Alliance is focused on the development of open, intelligent, virtualized and interoperable RAN specifications. The Alliance has already created 31 specifications, with 37 demonstrations of the technology at past MWC events, global plugfests, and more than 1 000 000 lines of code released in partnership with the Linux Foundation. Operators have begun to announce network implementations.
O-RAN Alliance’s mission and focus complements TIP’s mission of deploying end-to-end disaggregated telecom infrastructure in varying environments. With the liaison agreement O-RAN and TIP are now reaching a new level of collaboration for open RAN. The liaison allows for sharing information, referencing specifications and conducting joint testing and integration efforts.
“This new collaboration framework between O-RAN and TIP, two major initiatives in the area of open networking, will support our mission to re-shape the RAN industry towards open and intelligent mobile network infrastructure,” said Alex Jinsung Choi, COO of the O-RAN Alliance and SVP Strategy & Technology Innovation, Deutsche Telekom. “Alignment on O-RAN interoperability efforts will help the industry to speed up the delivery of commercial open RAN solutions. The establishment of the first joint O-RAN Open Test and Integration Center (OTIC) with the TIP Community Lab in Berlin is a concrete step to facilitate this multi-community approach.”
“TIP’s OpenRAN solutions are an important element of our work to accelerate innovation across all elements of the network including Access, Transport, Core & Services. Across the TIP community, we are seeing increasing demand and have achieved meaningful progress with OpenRAN deployments around the world,” said Attilio Zani, Executive Director, Telecom Infra Project. “With this collaboration framework in place, TIP and O-RAN will work together to develop interoperable 5G RAN solutions. One of our first outputs will be the release of the OpenRAN 5GNR NR Base Station Platform requirements document with normative references to the O-RAN specifications.”
About O-RAN Alliance
O-RAN Alliance is a world-wide community of more than 160 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, O-RAN Alliance’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN-compliant mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, O-RAN Alliance publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For a short video describing O-RAN’s progress, see www.o-ran.org/videos
For more information please visit www.o-ran.org
About Telecom Infra Project
TIP is a collaborative telecom community that is evolving the infrastructure that underpins global connectivity. TIP’s mission is to accelerate the pace of innovation in next generation telecom networks, through the design, build, test and deployment of standards-based, open and disaggregated end-to-end solutions. Over the past four years, TIP has driven substantial innovation across all elements of the network including Access, Transport, Core & Services, while spanning urban through to rural market use cases. To date, it has 13 Community Labs which test, validate and integrate solutions, embarked on field trials in Africa, Latin America, Middle East and Europe. The recently launched TIP Exchange hosts 45 products from 28 member companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom